US5284660A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Delayed onset transdermal delivery device
Assignee: Alza Corp
•
Filing: 1992-08-21
•
Granted: 1994-02-08
•
Expires: 2012-08-21
Abstract
Abstract A diffusional drug delivery device is described which can provide for delayed onset of therapeutic effect and for delivery of the therapeutic agent in predetermined temporal patterns at optimum rates. Delay means are provided between the agent reservoir and the surface through which the agent is released by diffusion to delay the release of agent at a therapeutic rate for predetermined times after application. Suitable means include a delay membrane disposed between the releasing surface and the agent reservoir, which membrane is preferably free of undissolved agent and/or is initially impermeable to the agent and thereafter becomes permeable. One or more agent chambers defined by one or more of such membranes may be provided, whereby agents are released in predetermined temporal patterns at optimal release rates. Delayed permeability enables programmed washout periods to be obtained from the sequential and concurrent application of devices for the administration of drugs, such as nitrates, to which patients may develop a tolerance on continuous administration over extended time periods.
Inventors
- 👤 Eun Soo Lee
- 👤 Felix Theeuwes
- 👤 Patrick S. L. Wong
- 👤 Su Il Yum
- 👤 Robert M. Gale
- 👤 Alejandro Zaffaroni
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-09 18:29
CPC Classifications
A; A61; A61M; A61M35/00; A61M35/003; A61K; A61K9/00; A61K9/70; A61K9/7023; A61K9/703; A61K9/7084; A61K9/7038; A61K9/7046; A61K9/7069; A61K9/7092
Claims Analysis
Total Claims: 32
Claim 1
Independent Claim
179 words
A controlled release dispensing device for delivering a drug to skin or mucosa and adapted to delay the onset of drug delivery at a therapeutically effective rate for a predetermined time after placement of said device in drug-transferring relationship to the skin or mucosa, said device comprising, in combination: a drug-containing reservoir having a surface through which said drug is released to the skin or mucosa, said drug being selected form the group consisting of nicotine and melatonin; and a drug release delay membrane comprised of hydrophilic or semihydrophilic polymer disposed between the skin or mucosa and the releasing surface of said reservoir, said delay membrane being substantially free of undissolved drug and being impermeable to said drug in a dry state and permeable thereto in a hydrated state; whereby said drug must pass through said delay membrane to reach the skin or mucosa and whereby release of said drug from said reservoir to the skin or mucosa at said therapeutically effective rate is delayed until the delay membrane is converted from its dry state to its hydrated state.
Claim 2
Dependent Claim
179 words
A controlled release dispensing device for delivering a drug to skin or mucosa and adapted to delay the onset of drug delivery at a therapeutically effective rate for a predetermined time after placement of said device in drug-transferring relationship to the skin or mucosa, said device comprising, in combination: a drug-containing reservoir having a surface through which said drug is released to the skin or mucosa, said drug being selected form the group consisting of nicotine and melatonin; and a drug release delay membrane comprised of hydrophilic or semihydrophilic polymer disposed between the skin or mucosa and the releasing surface of said reservoir, said delay membrane being substantially free of undissolved drug and being impermeable to said drug in a dry state and permeable thereto in a hydrated state; whereby said drug must pass through said delay membrane to reach the skin or mucosa and whereby release of said drug from said reservoir to the skin or mucosa at said therapeutically effective rate is delayed until the delay membrane is converted from its dry state to its hydrated state.
Claim 3
Dependent Claim
23 words
A device according to claim 1 wherein said delay membrane is converted from its dry state to its hydrated state by cutaneous liquids.
Claim 4
Dependent Claim
155 words
A delivery device for the percutaneous administration of a drug selected from the group consisting of nicotine and melatonin and adapted to delay the onset of drug delivery at a therapeutically effective rate for a predetermined time after placement of said device in drug-transmitting relationship to the skin or mucosa, said delivery device comprising; a backing layer impermeable to said drug; a drug-containing reservoir disposed between said backing layer and the skin or mucosa; a drug release delay membrane comprised of a hydrophilic or semihydrophilic polymer disposed between said reservoir and the skin or mucosa such that said drug must pass through said delay membrane to reach the skin or mucosa, said delay membrane being substantially free of undissolved drug and being impermeable to said drug when in a dry state and permeable to said drug when in a hydrated state; and means for maintaining said device in drug-transmitting relationship to the skin or mucosa.
Claim 5
Dependent Claim
155 words
A delivery device for the percutaneous administration of a drug selected from the group consisting of nicotine and melatonin and adapted to delay the onset of drug delivery at a therapeutically effective rate for a predetermined time after placement of said device in drug-transmitting relationship to the skin or mucosa, said delivery device comprising; a backing layer impermeable to said drug; a drug-containing reservoir disposed between said backing layer and the skin or mucosa; a drug release delay membrane comprised of a hydrophilic or semihydrophilic polymer disposed between said reservoir and the skin or mucosa such that said drug must pass through said delay membrane to reach the skin or mucosa, said delay membrane being substantially free of undissolved drug and being impermeable to said drug when in a dry state and permeable to said drug when in a hydrated state; and means for maintaining said device in drug-transmitting relationship to the skin or mucosa.
Claim 6
Dependent Claim
23 words
A device according to claim 3 wherein said delay membrane is converted from its dry state to its hydrated state by cutaneous liquids.
Claim 7
Dependent Claim
47 words
A device according to claim 3 which further comprises a second drug-containing reservoir disposed between said backing layer and the skin or mucosa and a second drug release delay membrane comprised of a hydrophilic or semihydrophilic polymer disposed between said second reservoir and the skin or mucosa.
Claim 8
Dependent Claim
35 words
A device according to claim 3 which further comprises a rate-controlling membrane for controlling the rate at which said delay membrane becomes hydrated when the device is placed in contact with the skin or mucosa.
Claim 9
Dependent Claim
31 words
A device according to claim 3 which further comprises a rate-controlling membrane for controlling the rate at which said drug is transmitted from said drug reservoir to the skin or mucosa.
Claim 10
Dependent Claim
14 words
A device according to claim 5 which further comprises at least one rate-controlling membrane.
Claim 11
Dependent Claim
32 words
A device according to claim 3 wherein said means for maintaining said device to the skin or mucosa comprises a contact adhesive disposed between said delay membrane and the skin or mucosa.
Claim 12
Dependent Claim
38 words
A device according to claim 9 wherein the total loading of drug in said contact adhesive at the time of application to the skin or mucosa is insufficient to establish and maintain drug delivery at a therapeutic rate.
Claim 13
Dependent Claim
21 words
A device according to claim 3 which further comprises an adhesive tie layer interposed between said delay membrane and said reservoir.
Claim 14
Dependent Claim
13 words
A device according to claim 3 wherein said delay membrane is polyvinyl alcohol.
Claim 15
Dependent Claim
11 words
A device according to claim 3 wherein said drug is nicotine.
Claim 16
Independent Claim
176 words
A method for delaying delivery of a drug selected form the group consisting of nicotine and melatonin to the skin or mucosa, said method comprising the steps of: 1) placing a delivery device onto the skin or mucosa, said device comprising; a backing layer impermeable to said drug; a drug-containing reservoir disposed between said backing layer and the skin or mucosa; a drug release delay membrane comprised of a hydrophilic or semihydrophilic polymer disposed between said reservoir and the skin or mucosa such that said drug must pass through said delay membrane to reach the skin or mucosa, said delay membrane being substantially free of undissolved drug and being impermeable to said drug when in a dry state and permeable to said drug when in a hydrated state; and means for maintaining said device in drug-transmitting relationship to the skin or mucosa; and 2) changing said delay membrane of said delivery device from said dry state to said hydrated state, whereby the passage of said drug from said reservoir to the skin or mucosa is delayed.
Claim 17
Independent Claim
176 words
A method for delaying delivery of a drug selected form the group consisting of nicotine and melatonin to the skin or mucosa, said method comprising the steps of: 1) placing a delivery device onto the skin or mucosa, said device comprising; a backing layer impermeable to said drug; a drug-containing reservoir disposed between said backing layer and the skin or mucosa; a drug release delay membrane comprised of a hydrophilic or semihydrophilic polymer disposed between said reservoir and the skin or mucosa such that said drug must pass through said delay membrane to reach the skin or mucosa, said delay membrane being substantially free of undissolved drug and being impermeable to said drug when in a dry state and permeable to said drug when in a hydrated state; and means for maintaining said device in drug-transmitting relationship to the skin or mucosa; and 2) changing said delay membrane of said delivery device from said dry state to said hydrated state, whereby the passage of said drug from said reservoir to the skin or mucosa is delayed.
Claim 18
Dependent Claim
27 words
The method according to claim 14 wherein said delay membrane is changed from its dry state to its hydrated state after placement on the skin or mucosa.
Claim 19
Dependent Claim
23 words
The method according to claim 14 wherein said delay membrane is changed from its dry state to its hydrated state by cutaneous liquids.
Claim 20
Dependent Claim
15 words
The method according to claim 14 wherein said delivery device further comprises a rate-controlling membrane.
Claim 21
Dependent Claim
13 words
The method according to claim 14 wherein said delay membrane is polyvinyl alcohol.
Claim 22
Dependent Claim
11 words
The method according to claim 14 wherein said drug is nicotine.
Claim 23
Independent Claim
170 words
A method for reducing the side effects associated with the transdermal delivery of nicotine during sleeping hours, said method comprising the steps of: 1) placing a delivery device onto the skin or mucosa prior to bedtime, said device comprising: a backing layer impermeable to nicotine; a nicotine-containing reservoir disposed between said backing layer and the skin or mucosa; a nicotine release delay membrane comprising polyvinyl alcohol disposed between said reservoir and the skin or mucosa such that nicotine must pass through said delay membrane to reach the skin or mucosa, said delay membrane being substantially free of undissolved nicotine and being impermeable to nicotine when in a dry state and permeable to nicotine when in a hydrated state; and means for maintaining said device in nicotine-transmitting relationship to the skin or mucosa; and 2) changing said delay membrane of said delivery device from said dry state to said hydrated state, whereby the passage of nicotine from said reservoir to the skin or mucosa is delayed until shortly prior to awakening.
Claim 24
Independent Claim
170 words
A method for reducing the side effects associated with the transdermal delivery of nicotine during sleeping hours, said method comprising the steps of: 1) placing a delivery device onto the skin or mucosa prior to bedtime, said device comprising: a backing layer impermeable to nicotine; a nicotine-containing reservoir disposed between said backing layer and the skin or mucosa; a nicotine release delay membrane comprising polyvinyl alcohol disposed between said reservoir and the skin or mucosa such that nicotine must pass through said delay membrane to reach the skin or mucosa, said delay membrane being substantially free of undissolved nicotine and being impermeable to nicotine when in a dry state and permeable to nicotine when in a hydrated state; and means for maintaining said device in nicotine-transmitting relationship to the skin or mucosa; and 2) changing said delay membrane of said delivery device from said dry state to said hydrated state, whereby the passage of nicotine from said reservoir to the skin or mucosa is delayed until shortly prior to awakening.
Claim 25
Dependent Claim
27 words
The method according to claim 20 wherein said delay membrane is changed from its dry state to its hydrated state after placement on the skin or mucosa.
Claim 26
Dependent Claim
23 words
The method according to claim 20 wherein said delay membrane is changed from its dry state to its hydrated state by cutaneous liquids.
Claim 27
Dependent Claim
15 words
The method according to claim 20 wherein said delivery device further comprises a rate-controlling membrane.
Claim 28
Independent Claim
183 words
A method for relieving the early morning withdrawal symptoms associated with low plasma concentrations of nicotine during sleeping hours, said method comprising the steps of: 1) placing a delivery device onto the skin or mucosa prior to bedtime, said device comprising: a backing layer impermeable to nicotine; a nicotine-containing reservoir disposed between said backing layer and the skin or mucosa; a nicotine release delay membrane comprising polyvinyl alcohol disposed between said reservoir and the skin or mucosa such that nicotine must pass through said delay membrane to reach the skin, said delay membrane being substantially free of undissolved nicotine and being impermeable to nicotine when in a dry state and permeable to nicotine when in a hydrated state; and means for maintaining said device in nicotine-transmitting relationship to the skin or mucosa; and 2) changing said delay membrane of said delivery device from said dry state to said hydrated state, whereby the passage of nicotine from said reservoir to the skin or mucosa is delayed until shortly prior to awakening, whereby therapeutic plasma levels of nicotine are present at the time of awakening.
Claim 29
Independent Claim
183 words
A method for relieving the early morning withdrawal symptoms associated with low plasma concentrations of nicotine during sleeping hours, said method comprising the steps of: 1) placing a delivery device onto the skin or mucosa prior to bedtime, said device comprising: a backing layer impermeable to nicotine; a nicotine-containing reservoir disposed between said backing layer and the skin or mucosa; a nicotine release delay membrane comprising polyvinyl alcohol disposed between said reservoir and the skin or mucosa such that nicotine must pass through said delay membrane to reach the skin, said delay membrane being substantially free of undissolved nicotine and being impermeable to nicotine when in a dry state and permeable to nicotine when in a hydrated state; and means for maintaining said device in nicotine-transmitting relationship to the skin or mucosa; and 2) changing said delay membrane of said delivery device from said dry state to said hydrated state, whereby the passage of nicotine from said reservoir to the skin or mucosa is delayed until shortly prior to awakening, whereby therapeutic plasma levels of nicotine are present at the time of awakening.
Claim 30
Dependent Claim
27 words
The method according to claim 24 wherein said delay membrane is changed from its dry state to its hydrated state after placement on the skin or mucosa.
Claim 31
Dependent Claim
23 words
The method according to claim 24 wherein said delay membrane is changed from its dry state to its hydrated state by cutaneous liquids.
Claim 32
Dependent Claim
15 words
The method according to claim 24 wherein said delivery device further comprises a rate-controlling membrane.
References Cited (Backward Citations)
US3598123A
Cited
US3948262A
Cited
US3598122A
Cited
US3598122B1
Cited
US3742951B1
Cited
US3742951A
Cited
US3923939A
Cited
US4144317A
Cited
US4031894A
Cited
US4201211A
Cited
US4286592A
Cited
US4314557A
Cited
US4379454A
Cited
US4568343A
Cited
US4655766A
Cited
US5141750A
Cited
US5071656A
Cited
US4917895A
Cited
US4781924A
Cited
US4837027A
Cited
US5004610A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1997-02-07 | 1997-08-09 | 1998-02-08 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2001-02-07 | 2001-08-09 | 2002-02-08 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2005-02-07 | 2005-08-09 | 2006-02-08 | $7700.00 | Window Closed / Lapsed |